CA
BIO icon

Capitolis Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capitolis Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,248
Closed -$713K – 414
2021
Q1 		$713K Hold
1,248
– – 0.01% 328
2020
Q4 		$728K Buy
+1,248
New +$711K 0.01% 434

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capitolis Advisors's BIO Position: Q2 2021 in Review

Capitolis Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2021, closing a stake of 1,248 shares — an estimated $713K sold.

Capitolis Advisors first reported a position in BIO in Q4 2020 and held it in 2 quarters. The position peaked at $728K in Q4 2020. 508 funds tracked by Wall St. Rank hold BIO as of Q2 2021.

  • Capitolis Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2021 after selling out during the quarter.
  • Capitolis Advisors sold 1,248 Bio-Rad Laboratories Class A shares in Q2 2021, an estimated $713K.
  • Capitolis Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 2 quarters.
  • Capitolis Advisors's Bio-Rad Laboratories Class A position peaked at $728K in Q4 2020.
  • 508 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2021.

Based on Capitolis Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.